> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 7 Observations on Lilly FDA-483
- URL: https://www.fdaweb.com/7-observations-on-lilly-fda-483/
- Published: 2021-08-03T12:00:00.000Z
- Updated: 2026-09-14T17:09:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149850

FDA has released the FDA-483 issued following a 2/18-3/16 inspection at the Eli Lilly sterile drug manufacturing facility in Indianapolis, IN. The seven inspection [observations](https://www.fda.gov/media/151142/download?ref=fdaweb.com) were: 

- failing to establish an adequate system for monitoring environmental conditions in aseptic processing areas;
- failing to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed;
- failing to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, including validation of all aseptic and sterilization processes;
- employees engaged in the manufacture, packing, and holding of a drug product lack the training required to perform their assigned functions;
- the written stability program for drug products does not include reliable, meaningful, and specific test methods;
- representative samples are not taken of each shipment of each lot of components and drug product containers for testing and examination; and
- the establishment of laboratory control mechanisms including any changes are not drafted by the appropriate organizational unit and reviewed and approved by the quality control unit.